Prevalence of all severities of hemophilia A and hemophilia B estimated at 17.1 and 3.8 cases per 100,000
TUESDAY, Sept. 10, 2019 (HealthDay News) — The expected number of patients with hemophilia worldwide is 1,125,000 male patients, with 418,000 severe cases, according to research published online Sept. 10 in the Annals of Internal Medicine.
Alfonso Iorio, M.D., Ph.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues estimated the prevalence and prevalence at birth of hemophilia in a random effects meta-analysis of registry data from Australia, Canada, France, Italy, New Zealand, and the United Kingdom.
The researchers found that per 100,000 men/boys, the prevalence was 17.1 and 6.0 cases for all severities of hemophilia A and for severe hemophilia A, respectively, and 3.8 and 1.1 cases for all severities of hemophilia B and severe hemophilia B, respectively. Per 100,000 men/boys, the prevalence at birth was 24.6 and 9.5 cases for all severities of hemophilia A and for severe hemophilia A, respectively, and 5.0 and 1.5 cases for all severities of hemophilia B and severe hemophilia B, respectively. For high-income countries, the life expectancy disadvantage was 30 and 37 percent for hemophilia A and severe hemophilia A, respectively, and 24 and 27 percent for hemophilia B and severe hemophilia B, respectively. Worldwide, the expected number of patients with hemophilia is 1,125,000; 418,000 of these should have severe hemophilia.
“Our analytic approach and results constitute a solid base for the future assessment of burden of disease in specific settings and worldwide,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Copyright © 2019 HealthDay. All rights reserved.
